FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Approved Oncology Drugs in Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Beximco Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 24, 2020

            Details:

            Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of Medical indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Polatuzumab Vedotin

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding January 21, 2020

            Details:

            Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology. It was developed and is commercialized by Roche/Genentech.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avapritinib

            Therapeutic Area: Oncology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Blueprint Medicines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 17, 2020

            Details:

            With nationwide distribution of AYVAKIT, PANTHERx establishes a formidable presence in the precision oncology space.